A Dose-Ranging, Phase II Study of the Efficacy and Safety of Alosetron in Men with Diarrhea-Predominant IBS
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A randomized, double blind, placebo-controlled dose-ranging study was conducted to assess the efficacy of alosetron in men with diarrhea-predominant irritable bowel syndrome (IBS). METHODS: Six hundred and sixty-two men were randomized to treatment with alosetron 0.5, 1.0, 2.0, 4.0 mg, or placebo twice daily for 12 wk, followed by a 4-wk posttreatment period. Adequate relief of IBS pain and discomfort during week 5-12 of the treatment phase was the primary endpoint; secondary endpoints included bowel urgency, stool frequency, and consistency, incomplete evacuation, bloating, and abdominal pain or discomfort. RESULTS: Subjects ranked urgency and abdominal pain as their most bothersome IBS symptoms. The average rate of adequate relief during week 5-12 was significantly higher in the alosetron 1.0 mg twice-daily group compared to placebo (53%vs 40%, p= 0.04), and all doses of alosetron significantly reduced stool consistency scores (p < 0.001) indicating firmer stools. No significant effects of alosetron were seen with regard to urgency, number of bowel movements, bloating, and incomplete evacuation. Constipation was the most common adverse event and occurred in a dose-related manner among subjects receiving alosetron, 9% (0.5 mg twice daily), 15% (1.0 mg twice daily), 11% (2.0 mg twice daily), and 21% (4.0 mg twice daily). No serious adverse events of constipation were reported. One subject in the 0.5 mg twice-daily group had an episode of rectal bleeding suggestive of a possible diagnosis of ischemic colitis. CONCLUSIONS: Alosetron 1 mg twice daily provided adequate relief of IBS pain and discomfort, and improved stool consistency in men with diarrhea-predominant IBS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functional bowel disorders and functional abdominal pain
Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & Müller-Lissner, S. A. (1999) · Gut · doi:10.1136/gut.45.2008.ii43 · Cited by 2,440
AGA technical review on irritable bowel syndrome.
Drossman, D. A., Camilleri, M., Mayer, E. A., & Whitehead, W. E. (2002) · Gastroenterology · doi:10.1053/gast.2002.37095 · Cited by 1,384
Self-citationBerkley, K. J. (1997) · Behavioral and Brain Sciences · doi:10.1017/s0140525x97221485 · Cited by 1,125
Sex differences in the perception of noxious experimental stimuli: a meta-analysis
Riley, J. L., Robinson, M. E., Wise, E. A., Myers, C. D., & Fillingim, R. B. (1998) · Pain · doi:10.1016/s0304-3959(97)00199-1 · Cited by 1,085
Gender differences in irritable bowel syndrome
Chang, L., & Heitkemper, M. M. (2002) · Gastroenterology · doi:10.1053/gast.2002.36603 · Cited by 351 · cited 1×
“Several explanations may account for the increased prevalence of IBS in women, including physiological differences between the sexes”
Self-citationTalley, N. J., Zinsmeister, A. R., & Melton, L. J. (1995) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a117548 · Cited by 327
Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome
Delvaux, M., Louvel, D., Mamet, J. ‐., Campos‐Oriola, R., & Frexinos, J. (1998) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1998.00375.x · Cited by 236 · cited 1×
“Alosetron has been shown to have beneficial effects on small bowel and colonic transit (21, 22), rectal compliance (23), and fluid absorption (24).”
BackgroundEfficacy of alosetron in irritable bowel syndrome: a meta‐analysis of randomized controlled trials
Cremonini, F., Delgado‐Aros, S., & Camilleri, M. (2003) · Neurogastroenterology & Motility · doi:10.1046/j.1365-2982.2003.00389.x · Cited by 219 · cited 1×
“As a consequence, constipation is the most common adverse event and occurs in dose-related manner among alosetron-treated subjects (34).”
BackgroundCondition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron
Berman, S. M., Chang, L., Suyenobu, B., Derbyshire, S. W., Stains, J., FitzGerald, L., Mandelkern, M., Hamm, L., Vogt, B., Naliboff, B. D., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.35990 · Cited by 139
Self-citationHoughton, Foster, & Whorwell (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00762.x · Cited by 132
Cited by
Enck, P., Aziz, Q., Barbara, G., Farmer, A. D., Fukudo, S., Mayer, E. A., Niesler, B., Quigley, E. M. M., Rajilić-Stojanović, M., Schemann, M., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.14 · Cited by 997
Self-citationFord, A. C., Moayyedi, P., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E. E., Spiegel, B. M. R., & Quigley, E. M. M. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.187 · Cited by 645
Drossman, D. A., Tack, J., Ford, A. C., Szigethy, E., Törnblom, H., & Van Oudenhove, L. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.11.279 · Cited by 470
American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome
Ford, A. C., Moayyedi, P., Chey, W. D., Harris, L. A., Lacy, B. E., Saito, Y. A., & Quigley, E. M. M. (2018) · American Journal of Gastroenterology · doi:10.1038/s41395-018-0084-x · Cited by 388
Chang, L., Toner, B. B., Fukudo, S., Guthrie, E., Locke, G. R., Norton, N. J., & Sperber, A. D. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.09.071 · Cited by 369
Self-citation
Metadata
- Authors
- Chang, L., Ameen, V. Z., Dukes, G. E., McSorley, D. J., Carter, E. G., & Mayer, E. A.
- Venue
- The American Journal of Gastroenterology
- Published
- 2005-01
- Volume
- 100
- Issue
- 1
- Pages
- 115-123
- ISSN
- 0002-9270 (ISSN-L)
- 1572-0241
- OpenAlex
- W2010780461
- Cited by
- 140
- References
- 10
- FWCI
- 8.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Dose-Ranging, Phase II Study of the Efficacy and Safety of Alosetron in Men with Diarrhea-Predominant IBS. https://app.cochat.ai/papers/10.1111/j.1572-0241.2005.40365.x
- The paper
- Chang, L., Ameen, V. Z., Dukes, G. E., McSorley, D. J., Carter, E. G., & Mayer, E. A. (2005). A Dose-Ranging, Phase II Study of the Efficacy and Safety of Alosetron in Men with Diarrhea-Predominant IBS. The American Journal of Gastroenterology. https://doi.org/10.1111/j.1572-0241.2005.40365.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.